Most cited papers from Arqule (United States)

Arqule (United States)

What are the most cited papers from Arqule (United States)?

The most cited paper from Arqule (United States) is "Towards a proteome-scale map of the human protein–protein interaction network" (Jean‐François Rual et al., 2005), with 3,034 citations. Next come "Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study" (558) and "Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma" (385).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 65 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Towards a proteome-scale map of the human protein–protein interaction network Jean‐François Rual et al. · Nature	27 Sep 2005	3,034
2	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Armando Santoro et al. · The Lancet Oncology	19 Nov 2012	558
3	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset et al. · British Journal of Cancer Open access	7 Nov 2018	385
4	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study Lorenza Rimassa et al. · The Lancet Oncology	3 Apr 2018	356
5	The effect of tobacco cessation on weight gain, obesity, and diabetes risk Terry M. Bush, Jennifer C. Lovejoy, Mona Deprey et al. · Obesity Open access	29 Aug 2016	231
6	Modular Synthesis of Heparin Oligosaccharides Hernán A. Orgueira, Alessandra Bartolozzi, Peter Schell et al. · Chemistry - A European Journal	30 Dec 2002	216
7	Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies Timothy Anthony Yap, David Olmos, Andre Tesainer Brunetto et al. · Journal of Clinical Oncology Open access	8 Mar 2011	196
8	Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users Phinikoula S. Katsamba et al. · Analytical Biochemistry	24 Feb 2006	186
9	Toward an Optimal Procedure for Variable Selection and QSAR Model Building Abdelaziz Yasri, David S. Hartsough · Journal of Chemical Information and Computer Sciences	Aug 2001	178
10	Automated parallel synthesis of chalcone-based screening libraries David G. Powers, David S. Casebier, Demosthenes Fokas et al. · Tetrahedron	Apr 1998	177
11	c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma Geoffrey Thomas Gibney, Saadia A. Aziz, Robert L. Camp et al. · Annals of Oncology Open access	30 Sep 2012	177
12	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation Sean D. Reiff et al. · Cancer Discovery Open access	9 Aug 2018	171
13	Multi-functional nanocarriers for targeted delivery of drugs and genes Lara Scheherazade Jabr-Milane, Lilian van Vlerken, Harikrishna Devalapally et al. · Journal of Controlled Release	30 Apr 2008	170
14	Binding of Polyubiquitin Chains to Ubiquitin-associated (UBA) Domains of HHR23A Shahri Raasi, Irina Orlov, Karen G. Fleming et al. · Journal of Molecular Biology	Aug 2004	160
15	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors Andrew J. Wagner, John M. Goldberg, Steven G. DuBois et al. · Cancer	17 May 2012	156
16	Regioselective synthesis of [1,2,3]-triazoles catalyzed by Cu(I) generated in situ from Cu(0) nanosize activated powder and amine hydrochloride salts Hernán A. Orgueira, Demosthenes Fokas, Yuko Isome et al. · Tetrahedron Letters	11 Mar 2005	150
17	Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197 Sudharshan Eathiraj, Rocio Palma, Erika Volckova et al. · Journal of Biological Chemistry Open access	25 Mar 2011	141
18	Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. David G. Gourley, Alexander W. Schüttelkopf, Gordon A. Leonard et al. · Nature Structural Biology	Jun 2001	139
19	Microwave-assisted one-pot synthesis of 2,3-disubstituted 3H-quinazolin-4-ones Jifeng Liu, Jaekyoo Lee, Audra M. Dalton et al. · Tetrahedron Letters	25 Jan 2005	137
20	Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential Mark F. Coughlin, Diane Renee Bielenberg, Guillaume Lenormand et al. · Clinical & Experimental Metastasis Open access	7 Sep 2012	128
21	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller et al. · Clinical Lung Cancer Open access	21 Mar 2012	126
22	Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092 Yi Yu, Ronald E. Savage, Sudharshan Eathiraj et al. · PLoS ONE Open access	15 Oct 2015	122
23	Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3 H -imidazo[4,5- b ]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry Open access	15 Jun 2016	117
24	Specific Structural Motifs Determine TRAP220 Interactions with Nuclear Hormone Receptors Yunsheng Ren, Evan Behre, Zhaojun Ren et al. · Molecular and Cellular Biology Open access	Aug 2000	117
25	Structure-based design of parasitic protease inhibitors Rongshi Li, Xiaowu Chen, Baoqing Gong et al. · Bioorganic & Medicinal Chemistry Open access	Sep 1996	115
26	Purification of Proteasomes, Proteasome Subcomplexes, and Proteasome-Associated Proteins From Budding Yeast David Leggett, Michael H. Glickman, Daniel Finley · Humana Press eBooks Book chapter	25 May 2005	114
27	Use of Support Vector Machine in Pattern Classification: Application to QSAR Studies Ryszard Czermiński, Abdelaziz Yasri, David S. Hartsough · Quantitative Structure-Activity Relationships	Oct 2001	111
28	Microwave-assisted one step high-throughput synthesis of benzimidazoles Shou‐Yuan Lin, Yuko Isome, E. Theal Stewart et al. · Tetrahedron Letters	10 Mar 2006	109
29	Discovery and Optimization of a Series of 3-(3-Phenyl-3 H -imidazo[4,5- b ]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors Mark A. Ashwell et al. · Journal of Medicinal Chemistry Open access	25 Apr 2012	109
30	Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis David E. Gerber, Muhammad Shaalan Beg, Farjana Jahan Fattah et al. · British Journal of Cancer Open access	Oct 2018	104
31	Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells Nish Patel, Sabarni K. Chatterjee, Vladimir D. Vrbanac et al. · Proceedings of the National Academy of Sciences Open access	25 Jan 2010	104
32	Novel One-Pot Total Syntheses of Deoxyvasicinone, Mackinazolinone, Isaindigotone, and Their Derivatives Promoted by Microwave Irradiation Jifeng Liu, Ye Ping, Kevin Sprague et al. · Organic Letters	22 Jun 2005	103
33	Detecting hidden sequence propensity for amyloid fibril formation Sukjoon Yoon, William Jeffrey Welsh · Protein Science Open access	23 Jul 2004	103
34	A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher et al. · British Journal of Cancer Open access	3 Oct 2017	97
35	Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome Kim M. Keppler‐Noreuil, Julie C. Sapp, Marjorie J. Lindhurst et al. · The American Journal of Human Genetics Open access	22 Feb 2019	95
36	Solution phase synthesis of a spiro[pyrrolidine-2,3′-oxindole] library via a three component 1,3-dipolar cycloaddition reaction Demosthenes Fokas, William J. Ryan, David S. Casebier et al. · Tetrahedron Letters	Apr 1998	93
37	Development of α-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease Youngchool Choe, Linda S. Brinen, Mark S. Price et al. · Bioorganic & Medicinal Chemistry	10 Feb 2005	91
38	Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation Terence G. Hall, Yi Yu, Sudharshan Eathiraj et al. · PLoS ONE Open access	14 Sep 2016	88
39	Three-Component One-Pot Total Syntheses of Glyantrypine, Fumiquinazoline F, and Fiscalin B Promoted by Microwave Irradiation Jifeng Liu, Ye Ping, Bailin Zhang et al. · The Journal of Organic Chemistry	Jul 2005	88
40	DUOX2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk Helmut Grasberger, Andrew T. Magis, Elisa Sheng et al. · Journal of Clinical Investigation Open access	2 Mar 2021	84
41	In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS) Carlotta Ranieri et al. · Neurogenetics Open access	16 Mar 2018	83
42	Macamides and their synthetic analogs: Evaluation of in vitro FAAH inhibition Hui Ming Wu, Charles J. Kelley, Alejandro J Pino‐Figueroa et al. · Bioorganic & Medicinal Chemistry Open access	27 Jun 2013	83
43	A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors Shubham Pant, Mansoor Noorali Saleh, Johanna C. Bendell et al. · Annals of Oncology Open access	16 Apr 2014	83
44	Combinatorial chemistry in drug discovery Joseph C. Hogan · Nature Biotechnology	Apr 1997	83
45	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity Madhav D. Sharma, Rafał Pacholczyk, Huidong Shi et al. · Immunity Open access	Oct 2021	81
46	Synthesis of 21,21-Difluoro-3β-hydroxy-20-methylpregna-5,20-diene and 5,16,20-Triene as potential inhibitors of steroid C17(20) lyase Philip M. Weintraub, Amy K. Holland, Cynthia A. Gates et al. · Bioorganic & Medicinal Chemistry	Feb 2003	79
47	A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis Armando Santoro, Matteo Simonelli, C Rodriguez-Lope et al. · British Journal of Cancer Open access	2013	78
48	Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib Jonathan Wade Goldman, Isett Laux, Feng Chai et al. · Cancer Open access	17 May 2012	77
49	Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection Zoya N. Demidenko, Claire Vivo, H. Dorota Halicka et al. · Cell Death and Differentiation	25 Nov 2005	77
50	The accelerated development of an optimized synthesis of 1,2,4-oxadiazoles: application of microwave irradiation and statistical design of experiments Marc D Evans, Jessica Ring, Adam William Schoen et al. · Tetrahedron Letters	Dec 2003	77

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.